Growth hormone deficiency secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Effective measures for the secondary prevention of growth hormone deficiency include
Patients who are receiving growth hormone therapy should be followed up 2-4 times per year. [[Growth]] rate usually increases during the first year of treatment, with an average increase of 8-10 cm/y. A slow [[Growth|growth rate]] more than expected should be investigated to exclude other causes such as [[hypothyroidism]] or [[inflammatory bowel disease]].


Most pediatric endocrinologists see patients who are receiving growth hormone therapy 2-4 times per year. The most important reasons for follow-up are to monitor growth progress and to adjust growth hormone dosage. Growth rate usually increases most during the first year of treatment, with an average increase of 8-10 cm/y (often called "catch-up" growth). Progressive growth slows over the next several years (ie, waning effect). A growth rate appearing to slow more than expected should prompt investigation for a medical cause (eg, hypothyroidism) or another diagnosis (eg, inflammatory bowel disease). Follow-up may also be needed to assure patient compliance with the growth hormone injections.
== Growth hormone deficiency secondary prevention ==
Effective measures for the [[secondary prevention]] of growth hormone deficiency include:
* Patients who are receiving growth hormone therapy should be followed up 2-4 times per year.  
* The most important reasons for follow-up are to monitor [[growth]] progress and to adjust [[growth hormone]] dosage.
* Follow-up may also be needed to assure patient compliance with the treatment.
* [[Growth]] rate usually increases during the first year of treatment, with an average increase of 8-10 cm/y.  
* Progressive [[growth]] slows over the next several years.  
* A slow [[Growth|growth rate]] more than expected should be investigated to exclude other causes such as [[hypothyroidism]] or [[inflammatory bowel disease]].  


==References==
==References==

Revision as of 14:16, 27 September 2017

Growth hormone deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Growth hormone deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Growth hormone deficiency secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Growth hormone deficiency secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Growth hormone deficiency secondary prevention

CDC on Growth hormone deficiency secondary prevention

Growth hormone deficiency secondary prevention in the news

Blogs on Growth hormone deficiency secondary prevention

Directions to Hospitals Treating Growth hormone deficiency

Risk calculators and risk factors for Growth hormone deficiency secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Patients who are receiving growth hormone therapy should be followed up 2-4 times per year. Growth rate usually increases during the first year of treatment, with an average increase of 8-10 cm/y. A slow growth rate more than expected should be investigated to exclude other causes such as hypothyroidism or inflammatory bowel disease.

Growth hormone deficiency secondary prevention

Effective measures for the secondary prevention of growth hormone deficiency include:

  • Patients who are receiving growth hormone therapy should be followed up 2-4 times per year.
  • The most important reasons for follow-up are to monitor growth progress and to adjust growth hormone dosage.
  • Follow-up may also be needed to assure patient compliance with the treatment.
  • Growth rate usually increases during the first year of treatment, with an average increase of 8-10 cm/y.
  • Progressive growth slows over the next several years.
  • A slow growth rate more than expected should be investigated to exclude other causes such as hypothyroidism or inflammatory bowel disease.

References

Template:WH Template:WS